Regulations and Reimbursement of Software as a Medical Device in Europe- Part1
With the advancement of technologies leading to a shift in how healthcare is administered and delivered, software has become an essential component of the development of medical devices. Particularly “Stand alone” software or “Software as a Medical Device (SaMD)” has seen fast growth recently as there is no hardware involved, fewer constraints as well as the use of fast feedback loops for improvement. Part 1 of this publication series from IQVIA – an associate member of AdvaMed® – explores SaMD definition, its challenges and the ways the regulatory bodies try to address them, as well as the expected development of regulations related to Artificial Intelligence (AI) and Machine Learning (ML) in SaMD.
Related Reading
Blog / Regulatory Affairs
Strengthen Your IDE Strategy at AdvaMed’s IDE Submissions Workshop
January 27, 2026
Gain in-depth IDE submission training, meaningful face time with FDA and regulatory leaders, and RAPS accreditation credits at AdvaMed’s IDE Submissions Workshop.
Resource / AdvaMed Advancements / Emerging Policy Response Resources / Global & Trade / Tariffs
AdvaMed® Advancements: Q4 2025 Report
January 27, 2026
AdvaMed® Advancements: Q4 2025 Report highlights how unified industry advocacy responded to policy disruption, trade uncertainty, and federal action impacting medtech.
Blog / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Health Access / Medical Imaging
Why the Health Tech Investment Act Matters: Peter Weems Breaks Down What This Means for Patients
January 26, 2026
In a new video developed in partnership with Patients Rising, AdvaMed’s Peter Weems, Vice President of Imaging Government Affairs and Policy Strategy, explains why the Health Tech Investment Act is critical to expanding patient access to FDA-authorized AI-enabled medical devices.
News / Coverage & Payment / Diagnostics / Regulatory Affairs
AdvaMed Names Brian J. Blaser, QuidelOrtho President and CEO, Chair of AdvaMedDx Board of Directors
January 21, 2026
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced that Brian Blaser, president and CEO of QuidelOrtho, will serve as the next chair of the AdvaMedDx Division Board of Directors, succeeding Thierry Bernard, CEO of QIAGEN. AdvaMedDx represents more than 70 manufacturers of the innovative in vitro diagnostic (IVD) tests critical to patient care.
News / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Medical Imaging / Regulatory Affairs
Medical Imaging Division Announces Rich Fabian as New Board Chair
January 16, 2026
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced that Rich Fabian, president and CEO of FUJIFILM Sonosite, will serve as the chair of the Medical Imaging division’s board of directors. He will succeed David Pacitti, CEO of Avanos Medical and former president and head of the Americas at Siemens Healthineers, the inaugural division board chair.
News / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Orthopedic / Regulatory Affairs
Robert Cohen of Stryker Named Chair of AdvaMed’s Digital Health Tech Division Board of Directors
January 5, 2026
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced that Robert Cohen, vice president, innovation and technology, orthopaedic group at Stryker, will be the next chair of the AdvaMed Digital Health Tech Board of Directors. He succeeds Dr. Taha Kass-Hout, global chief science and technology officer at GE HealthCare, who served as the inaugural chair of the board overseeing the then-newly created division.
News / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Medical Imaging / Orthopedic / Regulatory Affairs / Small Business
Mick Farrell, Chairman and CEO of Resmed, Named Chair of AdvaMed Board of Directors
December 11, 2025
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced Michael “Mick” Farrell, chairman and CEO of Resmed Inc. (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, will be the next chair of the AdvaMed Board of Directors. Farrell will serve a two-year term beginning in January 2026.
Event / Digital Health
Human Factors in the Digital MedTech Era: The Usability of Connected Technology
January 14, 2026
12:00 PM – 1:00 PM
Join EPAM as they explore how robust Human Factor practices can help teams navigate usability and compliance of products in an increasingly digital landscape.